Hereditary Multiple Exostoses—A Review of the Molecular Background, Diagnostics, and Potential Therapeutic Strategies

Ewelina Bukowska-Olech1,‡, Wiktoria Trzebiatowska2§, Wiktor Czech2§, Olga Drzymała2§, Piotr Frąk2§, Franciszek Klarowski2§, Piotr Klusek2§, Anna Szwajkowska2§ and Aleksander Jamsheer1,3*†

1Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland, 2Medical Student, Poznan University of Medical Sciences, Poznan, Poland, 3Centers for Medical Genetics GENESIS, Poznan, Poland

Hereditary multiple exostoses (HMEs) syndrome, also known as multiple osteochondromas, represents a rare and severe human skeletal disorder. The disease is characterized by multiple benign cartilage-capped bony outgrowths, termed exostoses or osteochondromas, that locate most commonly in the juxta-epiphyseal portions of long bones. Affected individuals usually complain of persistent pain caused by the pressure on neighboring tissues, disturbance of blood circulation, or rarely by spinal cord compression. However, the most severe complication of this condition is malignant transformation into chondrosarcoma, occurring in up to 3.9% of HMEs patients. The disease results mainly from heterozygous loss-of-function alterations in the EXT1 or EXT2 genes, encoding Golgi-associated glycosyltransferases, responsible for heparan sulfate biosynthesis. Some of the patients with HMEs do not carry pathogenic variants in those genes, hence the presence of somatic mutations, deep intronic variants, or another genes/loci is suggested. This review presents the systematic analysis of current cellular and molecular concepts of HMEs along with clinical characteristics, clinical and molecular diagnostic methods, differential diagnosis, and potential treatment options.

Keywords: hereditary multiple exostoses (HME), multiple osteochondromas (MO), diaphyseal aclasis, EXT1 gene, EXT2 gene, HME molecular background, HME diagnostics, HME therapeutic strategies

INTRODUCTION

Hereditary multiple exostoses (HMEs) syndrome, also known as multiple osteochondromas, hereditary deforming chondrodysplasia, multiple cartilaginous exostoses, or diaphyseal aclasis, was first described in a French family by Alexis Boyer in 1814 (Hennekam, 1991). It is a rare orphan disease with unknown exact incidence due to asymptomatic individuals that remain undiagnosed (Stieber and Dormans, 2005). However, some researchers estimate that HMEs occur in one per 50,000 in the Western population and affect more often males reaching male to female ratio as high as 1.5 (Schmale et al., 1994; Bovée, 2008; Ryckx et al., 2013; Paciﬁci, 2017).

HMEs develop in early childhood as benign multiple cartilage-capped bone tumors, i.e., osteochondromas, which ossify when skeletal growth is complete. The osteochondromas mainly involve long bone metaphyses and diaphyses, including ribs, but rarely also the scapula, vertebrae, pelvis, and sporadically the calvarial base (Figures 1, 2) (Stieber and Dormans, 2005; Sinha...
Consequently, affected individuals may present a reduction of skeletal growth, short stature, bone deformities, scoliosis, premature osteoarthritis, or compression of peripheral nerves (Wuyts et al., 1993; Vanhoenacker et al., 2001). However, the most severe complication of HME is a sporadic malignant transformation into chondrosarcoma (CHS), which risk depends on age, sex, genotype, and anatomical distribution of exostoses (Stieber and Dormans, 2005; Czajka and DiCaprio, 2015). One simple and valuable classification system, reflecting the severity of symptoms, was proposed by Mordenti et al. in 2013. It divides HMEs into three classes (I-III), depending on the presence or absence of the functional limitations and deformities. Additionally, each class includes two subclasses (A or B), which inform about the number of the affected body regions (Table 1) (Mordenti et al., 2013).

**MOLECULAR BACKGROUND**

HME syndrome results from pathogenic variants located within the EXT1 (8q24.11) and EXT2 (11p11.2) genes that cause HME type 1 (MIM: 133700) and type 2 (MIM: 133701), respectively (Ahn et al., 1995; Wuyts et al., 1995; Stickens et al., 1996; Hecht et al., 1997). A detailed summary of all reported mutation types identified in each gene was shown in Figure 3. Interestingly, some discrepancies in the prevalence of EXT1 and EXT2 mutations have been shown among various populations of HME patients, including individuals of Asian, Caucasian, and Latin American origin. In most of the ethnicities, pathogenic variants occur more often within the EXT1 gene (Figure 4). However, some exceptions were also reported in the medical literature such as results from Chinese HME patients’ screening that revealed the higher incidence of EXT1 mutations (71%, 12/17) than EXT1 (29%, 5/17) (Xu et al., 1999). Similarly, a recent report from Saudi Arabia revealed 54% (7/13) of mutations in the EXT2 gene and 46% (6/13) in the EXT1 gene (Al-Zayed et al., 2021). Interestingly, the subsequent two analyses performed among the Chinese put in question the previous results. Li et al. reported 57% (39/68) of pathogenic variants in the EXT1 gene and 43% (29/68) in the EXT2 gene (Li et al., 2018). Wang et al. have also described a higher incidence of EXT1 mutations, identified in 61% (11/18), whereas EXT2 variants in 39% (7/18) of all cases (Wang et al., 2020). On the other hand, two independent studies performed in Japanese patients gave fairly consistent results. In the first analysis, variants in the EXT1 gene accounted for 74% (17/23), whereas in EXT2 for 26% (6/23) (Seki et al., 2001). The second study revealed that 65% (34/52) of all mutations were identified in EXT1, while 35% (18/52) were localized in EXT2. Interestingly,
Causative alterations in EXT1 provide clear evidence that Fusco et al., 2019). Furthermore, data obtained from the Human Sarrión et al., 2013; Jamsheer et al., 2014; Santos et al., 2018; performed. Consequently, the presence of another yet cases without either patients remained molecularly undiagnosed. The percentage of present.

### CELLULAR BACKGROUND

Studies have proved that intracellular processes leading to the formation of osteochondromas depend on aberrant heparan sulfate (HS) biosynthesis. HS backbone formation is mediated by two glycosyltransferases encoded by the EXT1 and EXT2 genes (Majumdar, 1994; Busse-Wicher et al., 2014). HS is a linear polysaccharide belonging to the glycosaminoglycan (GAG) family, composed of repeated disaccharide units. HS chains may attach to “core protein”, forming one type of proteoglycans (PGs) called, in such a case, heparan sulfate proteoglycans (HSPGs). HSPGs are exposed on both the cellular membrane surface, i.e., pericellular and in an extracellular matrix (ECM), which plays a pivotal role in signal transduction of many molecules (Lopes et al., 2006). Thus, HSPGs and other PGs-GAGs are involved in various physiological and pathophysiological processes, such as receptor signaling, growth factor activation, cellular proliferation and differentiation, angiogenesis, and tumor metastasis (Trebcz-Geffen et al., 2008; Li and Kusche-Gullberg, 2016).

Glycosyltransferases encoded by the EXT1 and EXT2 genes are responsible for the biosynthesis of HSPG in the Golgi apparatus, where they compose a part of HS polymerase complex (Jones, 2011; Mikami and Kitagawa, 2013). In the following step, mature HPSGs are transported to the ECM and cell surface. Cells of the patients with HME have only one functional copy of either EXT1 or EXT2, being more prone to lose their ability of HS synthesis compared to cells of unaffected individuals. In the case of a second-hit somatic mutation, and thereby random inactivation of a second gene copy, the cells cease to synthesize functional HS. Therefore, mutations in the EXT1 and EXT2 genes cause critical impairment of the HS chain synthesis and elongation, which manifests with the low levels of the pericellular and extracellular HS (Alvarez et al., 2006). It has also been suggested that reduction of extracellular HS impairs chondrocytes growth and differentiation factor, i.e., Indian hedgehog (IHH) or other factors involved in the bone formation such as fibroblast growth factors (FGFs), bone morphogenetic proteins (BMPs), WNT-proteins or parathyroid hormone-related proteins (PTHrPS) (Yoon et al., 2006; Jones et al., 2014; Billings and Pacifi, 2015; Mundy et al., 2016).

Consequently, abnormalities in bone growth occur as the complete lack of HS or shortened HS chains impair chondrocytes differentiation and proliferation processes. Some perichondrial

### TABLE 1 Clinical hereditary exostoses (HMEs) classification obtained via Switching Neural Networks approach, proposed by Mordenti et al. (2016).

| Class | Subclass | A: ≤5 sites with exostoses | B: >5 sites with exostoses |
|-------|----------|---------------------------|--------------------------|
| I: deformities- no, functional limitations- no | A: ≤5 sites with deformities | B: >5 sites with deformities |
| II: deformities- no, functional limitations- present | A: 1 site with functional limitation | B: >1 site with functional limitation |
| III: deformities- present, functional limitations- present | A: 1 site with functional limitation | B: >1 site with functional limitation |

three families harbored variants in both genes (Ishimaru et al., 2016). The study performed among Brazilian, Italian, Polish, Spanish, and United Kingdom HME cohorts suggested that pathogenic variants more often localize in the EXT1 gene rather than in EXT2 gene (Figure 4) (Lonie et al., 2006; Sarrión et al., 2013; Jamsheer et al., 2014; Santos et al., 2018; Fusco et al., 2019). Furthermore, data obtained from the Human Gene Mutation Database (HGMD), provide clear evidence that the number of pathogenic variants in EXT1 is higher than causative alterations in EXT2 (Figure 3).

Notably, in all reported studies, a significant proportion of patients remained molecularly undiagnosed. The percentage of cases without either EXT1 or EXT2 causative alteration ranged from 4% up to 33%, depending on the type of mutational analyses performed. Consequently, the presence of another yet unidentified causative gene for HME, provisionally termed EXT3 and linked to chromosome 19p locus, was postulated (Le Merrer et al., 1994; Francannet et al., 2001). Second, mosaic mutations of the EXT1 or EXT2 genes may also account for HMEs in at least some of the patients negatively tested for germline mutations in both genes (Stieber and Dormans, 2005). One may also suspect the presence of deep intronic or regulatory variants in both EXT1 and EXT2 genes, which are undetectable using standard diagnostic methods, i.e., PCR followed by Sanger sequencing or targeted next-generation sequencing (NGS) methods, such as genes panel analysis and whole-exome sequencing (WES).
progenitor cells of chondrocytes, located within the growth plate, change their proliferation direction due to the loss of their polarity, forming exostoses. Chondrocytes in the elongation region group into vertical columns, and only cells located in the externals columns can form tumors. Cells placed inside the middle columns probably use regular length HS from vicinal chondrocytes. Thus not all cells with shortened HS chains give rise to bone tumors (Jones, 2011).

Pathological bone formations are usually found in long bones but rarely also in the flat ones (Alvarez et al., 2006). The schematic formation of HME was shown in Figure 5.

**MALIGNANT TRANSFORMATION**

Multiple cartilage-capped exostoses in the course of HMEs develop in childhood and ossify when skeletal growth is complete. The bony outgrowths are benign tumors, although they can transform into malignant CHS in 3.9% of patients (Jones et al., 2014; Pacifici, 2017; Fei et al., 2018). CHS transformation usually occurs before the age of 40 years, and in 87% of cases involves the appendicular skeleton with the most frequent localizations involving the pelvis followed by the scapula, proximal femur or spine, and the ribs. CHS is usually low-grade, but the main limitation for radical surgical excision may be the close location of the tumor to the principal neurovascular bundles. Several studies have suggested that individuals carrying EXT1 mutations are statistically at 1.5–2 times greater risk of malignant transformation than those harboring the EXT2 pathogenic variants (Fei et al., 2018).

**CLINICAL MANIFESTATION**

HMEs are rarely detected at birth. Usually, they gradually develop during childhood and adolescence and cease to grow once the
Epiphyseal plates become mature (Vanhoenacker et al., 2001; Pedrini et al., 2011). The average number of exostoses per patient is 15–18, however, it varies considerably among affected individuals and ranges from 2 to 172 osteochondromas (Bovée, 2008; Clement and Porter, 2014). HMEs may develop in bones formed in the process of endochondral ossification, most frequently long bones. One of the most commonly involved body regions comprises the knee area, with exostoses occurring predominantly in the distal femur (70%), proximal tibia (71%), and proximal fibula (27%). Although HMEs predominantly locate in the skeleton of the lower extremities, other frequently affected bones include humerus (50%), ulna and radius (30%) (Schmale et al., 1994). Less common locations involve hands, ribs, scapulae, vertebrae, and pelvis (Figure 2) (Guo et al., 2014).

The clinical severity of the disease depends on the total number of exostoses as well as their size and shape. Osteochondromas typically project away from the epiphysis and may be pedunculated or sessile. The osseous tuber is called pedunculated when it is slender and has a narrow stalk. This form tends to irritate the surrounding tissues, leading to local trauma. The sessile tuber has semicircular or mound shape and attaches to the bone with a broader base (Figure 1). Some authors suggest that pedunculated morphology and the massive exostoses with greater cortical involvement associate with notable shortening of an involved bone (Stieber and Dormans, 2005).

The exostoses in their non-transformed form are benign lesions that can remain almost asymptomatic until they are detected by palpation. Unfortunately, the majority of patients are symptomatic, as over 80% of them experience pain, which is the most common disease complaint (Darilek et al., 2005). Pain may arise secondary to the irritation of structures adjacent to bone tubers, e. g. muscles, tendons, blood vessels, peripheral nerves, spinal cord, but also from joint malalignment or bursitis. Exostoses are usually located in the proximity of joints, limiting their range of motion, restricting their flexion or rotation (Jäger et al., 2007; Clement and Porter, 2014). Due to an outgrowth of the epiphyseal plate, osteochondroma may interfere with skeletal development and give rise to limb deformities. Disproportionate bone shortening can result in joint malalignment, bowing, subluxation, or dislocation of adjacent bones. These deformities include Madelung-type deformities of the wrist, hand involvement (including brachydactyly, pseudomallet fingers, angular deformity), coxa valga, acetabular dysplasia, genu valgum, and valgus angulation of ankle joint (Vanhoenacker et al., 2001; Stieber et al., 2011).
and Dormans, 2005; Beltrami et al., 2016). Limb length discrepancy is frequent and, in many cases, requires surgical interventions. Apart from the local effects of osteochondromas, a widespread influence of HME on skeletal system development was also suggested. Matsumoto et al. showed that more than half of HME patients present with mild to moderate scoliosis, independent of lower limb deformity or the number of osteochondromas (Matsumoto et al., 2015). Another systemic influence associated with HME is short stature. The skeletal age in younger children with HME is retarded in reference to their metrical age, while for adolescents, it is accelerated, suggesting an earlier closure of the growth plates (Staal et al., 2015). In general, most adult patients’ height is below average but within a normal range (Goud et al., 2012).

Rare and atypical complications of HME may also occur. First, thoracic exostoses have been reported to give rise to pneumothorax, diaphragmatic rupture, hemothorax, coronary artery compression, and severe chest pain (Wyants et al., 1993; Vanhoenacker et al., 2001; Cowles et al., 2005; Ravindran et al., 2015). Second, cervical osteochondromas have been found to cause neurogenic and vascular thoracic outlet syndrome as well as dysphagia (Gulati et al., 2013; Abdolrazaghi et al., 2018). Finally, a malignant transformation can develop in 3.9% of all affected patients, being the most severe complication of HME (Czajka and DiCaprio, 2015; Jurik, 2020). Malignant transformation occurs more frequently in particular anatomical regions such as the pelvis, scalpula, and proximal part of the femur. Tumors arising from endochondral elements of the cranium and defects of the cranial base, especially clivus, are also common but often overlooked in the diagnostic screening (Sinha et al., 2017).

**DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS**

The first symptoms of HME are frequently noticed by the parents when the patient is 5–7 years old and recognized because of disabilities in gross and minor motor skills or local pain, which develops due to osteochondromas’ pressure on the neighboring tissues (Czajka and DiCaprio, 2015; D’Arienzo et al., 2019). The clinical HME diagnosis is based on imaging tests such as X-rays, CT or MRI. The disease is recognized when at least two osteochondromas are identified in an individual, and other possible diagnoses are simultaneously excluded (D’Arienzo et al., 2019). The lesions mainly localize at the surface of the bone and in the metaphyseal regions, and to be considered bona fide osteochondromas, they need to maintain contact with the underlying parent bone cortex and the medullary canal (Murphey et al., 2000; Alabdullrahman and Byerly, 2021). As HMEs may clinically overlap with several other diseases, the differential diagnosis presented in Table 2 should be considered.

Radiological imaging is recommended and usually becomes the first step of the diagnostic process. However, it is sufficient only when HMEs localize within long bones (D’Arienzo et al., 2019). Upon radiographic imaging, the characteristic sign of exostoses includes a marked borderline between the tumor and the healthy bone. In addition, CT and MRI more accurately identify skeletal changes in the abdominal cavity and the pelvis due to limited accessibility of these locations to standard X-ray imaging (Kok et al., 2013; Beltrami et al., 2016). Moreover, MRI allows for detailed visualization of bone structures, including distinction between benign and malignant tumors. Even if new tumors no longer occur after the inhibition of bone development at about 20–25 years of age, there is still a possibility of malignant transformation into CHS. Therefore, a whole-body MRI scan should be implemented as screening for early detection of CHS in patients with HME, regardless their age (Kok et al., 2013; Jurik et al., 2020). Herget et al. e. propose that MRI should be performed once a year (Herget et al., 2013). Also, preoperative MRI is recommended to reduce postoperative complications resulting from unidentified intraspinal exostoses (Vu et al., 2020).

Other under-estimated and rarely implemented methods in HME diagnosis include single positron emission computer scan (SPECT-CT) and specific biomarkers analysis. Although SPECT-CT is rarely performed due to its low availability and high cost, Van den Wyngaert was fairly enthusiastic about the possibilities of this method regarding its sensitivity and specificity compared to CT imaging or bone scintigraphy (Van den Wyngaert et al., 2020). Likewise, Wang emphasizes that SPECT-CT has an excellent diagnostic value as the method of bone disease diagnosis (Wang et al., 2018).

In addition to imaging methods, the highest specificity for HME diagnosis confers genetic testing, which can identify the disease even before the development of the first symptoms, giving a possibility to plan a long-term follow-up (Medek et al., 2017). Genetic counseling is particularly recommended for adults who have a child with HME to estimate the risk of the disease in the future offspring as well as adults with HME who plan a pregnancy. Still, molecular testing seems indispensable in the postnatal screening of children born to affected individuals and their relatives at risk (Liag et al., 2020). As only two genes, i.e., EXT1 or EXT2, have been linked with HME thus far, they are routinely screened to detect point mutations, intragenic deletions or duplications, or rarely, more complex rearrangements. Methods that have been implemented for causative mutation screening involve PCR followed by Sanger sequencing, MLPA (MRC Holland kits), quantitative PCR, or, if available, next-generation sequencing-based methods.

Finally, Anower-e-Khuda et al. revealed the potential biochemical markers available for testing in individuals’ blood, such as HS/chondroitin sulfate (CS) ratio or HS level. Both HS/CS ratio and HS level decrease in the course of HME. The HS/CS ratios of HMEs patients were almost half of those identified in healthy controls (Anower-E-Khuda et al., 2013).

**TREATMENT AND NOVEL THERAPEUTIC STRATEGIES**

Current methods of HME treatment bases on surgical removal of exostoses, especially those symptomatic or causing damage and irritation to the local structures. In the case of asymptomatic osteochondromas, no therapy is implemented. Surgical treatment
TABLE 2 | A comparison of hereditary multiple exostoses (HMEs) and other disorders presenting overlapping clinical features (Maas et al., 1993; Pignolo et al., 2013; McFarlane et al., 2016; Beyens et al., 2019; Junk, 2020; Suster et al., 2020; Trajkova et al., 2020; Charita et al., 2021).

| Disease                          | Similarities*                                                                 | Differences*                                                                 |
|---------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Metachondromatosis              | multiple exostoses and enchondromas                                            | pathogenic variants in the PTEN11 gene in some individuals                   |
| Ollier disease and Maffucci syndrome | multiple enchondromas                                                        | somatic mosaic pathogenic variants in the IDH1, IDH2; PTH1R genes in some individuals |
| Langer–Giedion syndrome         | multiple exostoses, growth retardation, EXT1 loss of function mutations       | distinctive facial features, ectodermal features, intellectual disability in some individuals, partial interstitial deletion of the chromosome 8 (8q24), including the EXT1 and TRPS1 gene |
| Potocki–Shaffer syndrome         | multiple exostoses EXT2 loss of function mutations                            | biparietal foramina, neurodevelopmental delay, intellectual disability, facial dysmorphism, partial interstitial deletion of the chromosome 11 (11p11.2), including the EXT2, ALX4 and PHF21A genes |
| Fibrodysplasia ossificans progressiva | numerous bone tumors                                                       | foci of ectopic ossification, ossifying changes of muscular and other tissues, hypoplastic or absent hallucae, pathogenic variants in the ACVR1 gene |
| Menkes disease (Occipital horn syndrome) | bony exostoses                                                               | cuts laxa and bladder diverticula, pathogenic variants in the ATP7A gene |
| Gardner syndrome                | multiple exostoses                                                            | numerous adenomatous polyps in gastrointestinal tract, dental anomalies, skin changes, malignant tumors in various locations, variants in the APC gene |

*to HMEs.

TABLE 3 | The presentation of potential treatment targets in hereditary multiple exostoses (HME) (Yoon et al., 2006; Bovée et al., 2010; Heuzé et al., 2014; Huegel et al., 2015; Mundy et al., 2016; Sinha et al., 2017; Inubushi et al., 2018; Pacifi, 2018).

| Potential treatment target       | Clarification                                                                 |
|---------------------------------|-------------------------------------------------------------------------------|
| BMP signaling pathway           | BMP (bone morphogenetic protein) signaling plays an essential role in skeletal development by regulating chondrocyte proliferation and differentiation. Inubishi et al. showed the connection between increased BMP signaling and osteochondromagenesis. In addition, they suggested that treatment with BMP inhibitor may be effective in HME patients, which was proved by the promising results of their study conducted on mouse models. Administration of BMP inhibitor LDN-193189 presented a suppressive effect on osteochondroma formation. Another study in mice brought similar results |
| Hedgehog signaling pathway      | The hedgehog signaling pathway regulates the proliferation of growth plate chondrocytes. In this regard, the response to the potential treatment of HME with Hedgehog Signaling Antagonist (HhAntag) has been investigated. Studies in vitro not only demonstrated an effective block in chondrogenesis but in addition, inhibition in the BMP signaling pathway has been observed, showing the complexity of mechanisms involved in these processes |
| Heparanase                       | Heparanase, an enzyme that cleaves the heparan sulfate (HS) chains and stimulates chondrogenesis, is physiologically found only in the hypertrophic zone and perichondrium. Its wider distribution and increased activity possibly play a role in the development of osteochondromas. An in vitro study showed that a heparanase antagonist SST0001 successfully inhibited chondrogenesis. It suggests that further investigation may be profitable |

intends to relieve chronic pain reported by most patients and prevent them from skeletal deformities, which often include growth asymmetry, resulting f. e. in limb length discrepancy. Moreover, it is performed to restore the motion of joints, improve circulation hampered by vessel compression, or for cosmetic purposes (Stieber and Dormans, 2005; Bovée, 2008). However, complete excision of osteochondromas in some regions may not be possible (Phan et al., 2018). Additionally, as shown in the study published in 2012, patients with HME present a lower Health-Related Quality of Life factor in comparison with the control group (Chhina et al., 2012). For these reasons and because of everyday life discomfort experienced by many patients, new potential treatments need to be investigated (Sabir and Cole, 2019).

In HME, at the cellular level, the biosynthesis of heparan sulfate is affected, which is crucial for the proper functioning of many metabolic pathways. It mainly involves the FGF, BMP, hedgehog, and retinoid signaling pathways, out of which any can turn out to be a potential treatment target (Huegel et al., 2013; Pacifi, 2018). Extensive research has been done on the most promising potential drug, i.e., palovarotene (PVO), a selective agonist of retinoic acid receptor γ, present in chondrocytes and mesenchymal precursor cells. Its mechanism of action is connected with blocking chondrogenesis and cartilage development at the level of retinoid signaling. Previous studies revealed that chondrogenesis and growth plate functioning are enhanced by silencing of retinoid signaling (Hofiman et al., 2003). Furthermore, it involves the repressive mechanism of retinoic acid receptors (RAR), which—when unliganded with retinoic acid—exert repressor function to the target genes in the nucleus (Weston et al., 2002; Shimono et al., 2011; Pacifi, 2018). Studies performed in vitro as well as in mouse and rat models have shown that active retinoids can block the process by enhancing retinoid signaling, leading to suppression of
chondrogenesis (Wang et al., 2014; Inubushi et al., 2018). In 2018, Clementia Pharmaceuticals Inc. (now incorporated by Ipsen group) launched a phase two, randomized, double-blind, placebo-controlled clinical trial on PVO efficacy and safety in patients with HME (ClinicalTrials.gov Identifier: NCT03442985). However, the FDA partially suspended the study in 2019 due to the reports about early growth plate closure in children treated with PVO in another clinical trial regarding fibrodyplasia ossificans progressiva (FOP). The study of PVO treatment in patients with HME was eventually terminated in October 2020 to analyze collected data. No reports describing the results and treatment efficacy have been released yet.

Other potential and promising treatment targets are presented in Table 3. They include BMP and Hedgehog signaling pathways or an enzyme heparanase (Yoon et al., 2006; Bovée et al., 2010; Heuzé et al., 2014; Huegel et al., 2015; Mundy et al., 2016; Sinha et al., 2017; Inubushi et al., 2018; Pacifi, 2018).

CONCLUSION

HME is a rare pediatric skeletal disease in which benign tumors next to bone growth plates develop. The disease may severely affect the quality of patients’ life due to motion impairments, skeletal deformations, chronic pain, or growth retardation and possibility of malignant transformation of exostoses. Despite the studies on potential causal therapies, the only available treatment options are surgical removal of the most symptomatic tumors, correction of skeletal defects, and analgesic interventions. Although the treatment strategies are limited, the precise diagnosis, which can be obtained only by molecular methods, seems to be crucial in patients management. Hence, future directions should focus on revealing the molecular cause in individuals with HME and negative EXT1 and EXT2 mutational screening and better molecular diagnostics of pediatric patients. In addition, the second reachable goal should aim at early recognition of HMEs malignant transformation and its better understanding at the molecular and cellular level. Achieving the above will probably reveal new treatment options or therapeutic targets in both HMEs and CHS.

REFERENCES

Abdolrazaghi, H., Riyahi, A., Taghavi, M., Farshidmehr, P., and Mohammadbeigi, A. (2018). Concomitant Neurogenic and Vascular Thoracic Outlet Syndrome Due to Multiple Exostoses. Ann. Card. Anaesth. 21, 71–73. doi:10.4103/acca.ACA.119_17

Ahn, J., Ludecke, H.-J., Lindow, S., Horton, W. A., Lee, B., Wagner, M. J., et al. (1995). Cloning of the Putative Tumour Suppressor Gene for Hereditary Multiple Exostoses (EXT1). Nat. Genet. 11, 137–143. doi:10.1038/ng1095-137

Al-Zayed, Z., Al-Rijilal, R. A. A., Ghofaili, L., BinEssa, H. A., Pant, R., Abrahial, A., et al. (2021). Mutation Spectrum of EXT1 and EXT2 in the Saudi Patients with Hereditary Multiple Exostoses. Orphanet J. Rare Dis. 16, 100. doi:10.1186/s13023-021-01738-z

Alabdullrahman, L. W., and Byerly, D. W. (2021). Osteochondroma. Treasure Island (FL): StatPearls Publishing.

Alvarez, C., Tredwell, S., De Vera, M., and Hayden, M. (2006). The Genotype-Phenotype Correlation of Hereditary Multiple Exostoses. Clin. Genet. 70, 122–130. doi:10.1111/j.1399-0004.2006.00653.x

Anower-E-Khuda, M. F., Matsumoto, K., Habuchi, H., Morita, H., Yokochi, T., Czajka, C. M., and DiCaprio, M. R. (2015). What Is the Proportion of Patients with Brodysplasia? Genet. Med. 17, 528. doi:10.1038/gene.2015.30

Beyens, A., Meensel, K., Baeke, F., et al. (2019). Hereditary Multiple Exostosis: A Systematic Review and Clinical and Metabolic Characteristics in Occipital Horn Syndrome: Two New Cases and Review of the Literature. Genes 10, 528. doi:10.3390/genes10050528

AUTHOR CONTRIBUTIONS

EB-O was responsible for conceptuality, drafting, writing, corrections, preparing figures; WT, WC, OD, PF, FK, PK, and AS were responsible for drafting, writing, preparing figures and tables; AJ was responsible for conceptuality, drafting, writing, and corrections.

FUNDING

This work was supported by the grant from the Polish National Science Centre UMO-2016/22/E/NNZ/00270 to AJ.
